Compugen announces USPTO grants new patent for use of COM902

Compugen (CGEN) announced that the United States Patent and Trademark Office has granted the company a new patent covering method of use for COM902, the company’s potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer. U.S. Patent No. 12152084 titled “Triple combination antibody therapies” augments patents previously issued to Compugen by expanding and protecting the use of COM902 and backup antibodies for treating cancer patients, to include the triplet combination of COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody.